Clinical Aspects and Management of Levodopa-Induced Dyskinesia-Reference-Cited by-同舟云学术

Clinical Aspects and Management of Levodopa-Induced Dyskinesia

Published:2012 Issue: Volume:2012 Page:1-12
ISSN:2090-8083
Container-title:Parkinson's Disease
language:en
Short-container-title:Parkinson's Disease

Author:

Tambasco Nicola¹^ORCID,Simoni Simone¹,Marsili Erica¹,Sacchini Elisa¹,Murasecco Donatella¹,Cardaioli Gabriela¹,Rossi Aroldo¹,Calabresi Paolo¹²

Affiliation:

1. Clinica Neurologica, Azienda Ospedaliera—Università di Perugia, S. Andrea delle Fratte, 06156 Perugia, Italy

2. IRCCS Fondazione S. Lucia, Via Ardeatina 306, 00179 Roma, Italy

Abstract

In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa dosing or the early use of dopamine agonists. Dopamine agonists with different pharmacological profile are available. Our paper was aimed to analyse the clinical impact and the management of dyskinesias with dopamine agonists.

Publisher

Hindawi Limited

Subject

Psychiatry and Mental health,Neurology (clinical),Neuroscience (miscellaneous)

Link

http://downloads.hindawi.com/journals/pd/2012/745947.pdf

Reference123 articles.

1. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap

2. Treatment of levodopa-induced motor complications

3. Levodopa-induced breathing, cognitive and behavioral changes in Parkinson’s disease

4. Pharmacokinetics and pharmacodynamics of levodopa

5. Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson Disease

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II;Frontiers in Neurology;2022-08-23

2. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic;Neurodegenerative Disease Management;2022-08

3. The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials;Frontiers in Aging Neuroscience;2022-04-22

4. Carboxylated single-wall carbon nanotubes decorated with SiO2 coated-Nd2O3 nanoparticles as an electrochemical sensor for L-DOPA detection;Microchemical Journal;2021-09

5. Promising drug targets and associated therapeutic interventions in Parkinson’s disease;Neural Regeneration Research;2021